What the Yale Secret Shopper Study Means for How You Choose a Prescriber

GLP-1 Prescriptions Editorial Team · July 17, 2026 · 8 min read
Affiliate Disclosure: This site contains affiliate links to telehealth providers. If you click a link and make a purchase, we may receive a commission at no extra cost to you. All opinions are our own. Links marked "Paid link" are sponsored placements. See our full disclosure.

The Study That Shook the Industry

On July 6, 2026, JAMA published a secret shopper study from Yale School of Medicine that quantified what many suspected: getting a GLP-1 prescription online is remarkably easy, and the quality of medical oversight varies enormously between platforms. A Yale medical student created a patient profile — a 27-year-old male qualifying for a GLP-1 — and attempted to obtain prescriptions from 49 different websites selling branded or compounded semaglutide and tirzepatide.

The numbers were striking: 45 of 49 websites (91.8%) issued a prescription. Approximately 67% required no interaction with a clinician at all — the "evaluation" consisted entirely of a patient-reported questionnaire. Some platforms approved prescriptions within 5 minutes of the application, and 69.4% shipped medication within 24 hours.

What This Means for You Personally

The study doesn't mean telehealth GLP-1 prescribing is universally dangerous. It means the range of quality is enormous. Some platforms provide thorough medical evaluations with qualified prescribers who review your history, screen for contraindications, and maintain ongoing clinical relationships. Others are essentially vending machines with a prescriber's signature attached.

Your job as a patient is to distinguish between the two. The study gives you a framework for doing that: look for the specific quality markers that the weakest platforms lacked.

Editor's Choice

Embody

Top Pick — $400 CPA

From $249/mo

Injectable semaglutide only. Compounded — not FDA-approved.

Check Eligibility →

The Quality Checklist Based on Yale's Findings

The Bottom Line: Use the Yale study as a screening tool, not a reason to avoid telehealth entirely. Telehealth has legitimate advantages — speed, convenience, access, cost. The key is choosing a platform that takes the medical evaluation as seriously as it takes the sales funnel.

Platforms That Got It Right

The study also found platforms that maintained appropriate clinical standards while still operating efficiently. These platforms typically required a medical history review, offered clinician communication channels, screened for safety-relevant conditions, and didn't approve prescriptions in minutes.

When evaluating a telehealth GLP-1 platform, ask: "How will I interact with my prescriber?" "What happens if I have a question after my prescription is written?" "Do you screen for thyroid conditions and eating disorders?" "How quickly does the average patient get approved?" If the answer to the last question is "minutes," consider whether the answers to the first three questions are satisfactory.

Data-Driven

Wellorithm

Science-Forward

From $199/mo

Compounded — not FDA-approved.

Check Eligibility →
Brand-Name Rx

Sesame Care

Brand-Name Marketplace

From $99/visit

FDA-approved brand-name medications only (Wegovy, Zepbound, Foundayo). Not compounded.

Check Eligibility →
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. GLP-1 receptor agonists are prescription medications with potential side effects including nausea, vomiting, diarrhea, and in rare cases, pancreatitis or thyroid tumors. Do not use if you have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Always consult a licensed healthcare provider before starting any medication. Compounded medications are not FDA-approved for safety, efficacy, or quality.